CRL - Charles River Laboratories International, Inc.
NEXT EARNINGS:
May 6, 2026
EPS Est: $2.52
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$201.14
DETAILS
HIGH:
$260.00
LOW:
$175.00
MEDIAN:
$195.00
CONSENSUS:
$201.14
UPSIDE:
21.12%
Market Cap:
8.17B
Volume:
648,292
Avg Volume:
869,671
52 Week Range:
91.86-228.88
Sector:
Healthcare
Industry:
Medical - Diagnostics & Research
Beta:
1.62
Last Dividend:
$N/A
Exchange:
NYSE
Country:
US
Employees:
18,700
IPO Date:
2000-06-23
EPS (TTM):
-2.91
P/E Ratio:
-69.93
Revenue (TTM):
4.02B
Total Assets:
7.14B
Total Debt:
3.07B
Cash & Equiv:
213.77M
Rev Growth (5Y):
7.4%
EPS Growth (5Y):
-41.0%
FCF Growth (5Y):
7.3%
ROCE:
8.4%
Debt/Equity:
0.97
Earnings History
| Date | EPS Actual | EPS Est | EPS Surprise | Rev Actual | Rev Est | Rev Surprise |
|---|---|---|---|---|---|---|
| 2026-02-18 | $-5.62 | $2.33 | -341.2% | $994.2M | $998.1M | -0.4% |
| 2025-11-05 | $2.43 | $2.32 | +4.7% | $1.0B | $987.2M | +1.8% |
| 2025-08-06 | $3.12 | $2.50 | +24.8% | $1.0B | $968.9M | +6.5% |
| 2025-05-07 | $2.34 | $2.06 | +13.6% | $984.2M | $958.8M | +2.6% |
| 2025-02-19 | $2.66 | $2.50 | +6.4% | $1.0B | $948.2M | +5.7% |
| 2024-11-06 | $2.59 | $2.42 | +7.0% | $1.0B | $976.0M | +3.5% |
| 2024-08-07 | $2.80 | $2.39 | +17.2% | $1.0B | $1.0B | +0.2% |
| 2024-05-09 | $2.27 | $2.06 | +10.2% | $1.0B | $992.3M | +1.9% |
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 4.02B | 4.05B | 4.13B | 3.98B | 3.54B | 2.92B | 2.62B | 2.27B | 1.86B | 1.68B | 1.36B | 1.30B |
| Net Income | (144.34M) | 10.30M | 474.62M | 486.23M | 390.98M | 364.30M | 252.02M | 226.37M | 123.36M | 154.76M | 149.31M | 126.70M |
| EPS | -2.91 | 0.20 | 9.27 | 9.57 | 7.77 | 7.35 | 5.17 | 4.72 | 2.60 | 3.29 | 3.21 | 2.72 |
| Total Assets | 7.14B | 7.53B | 8.20B | 7.60B | 7.02B | 5.49B | 4.69B | 3.86B | 2.93B | 2.71B | 2.07B | 1.89B |
| Total Debt | 3.07B | 2.72B | 3.07B | 3.10B | 3.21B | 2.16B | 2.02B | 1.70B | 1.15B | 1.24B | 863.03M | 777.86M |
| Cash & Equivalents | 213.77M | 194.61M | 276.77M | 233.91M | 245.24M | 228.42M | 238.01M | 195.44M | 163.79M | 117.63M | 117.95M | 160.02M |
| Operating Cash Flow | 737.65M | 734.58M | 683.90M | 619.64M | 760.80M | 546.58M | 480.94M | 441.14M | 316.26M | 298.32M | 286.36M | 251.05M |
| Free Cash Flow | 518.49M | 501.61M | 365.37M | 294.91M | 532.03M | 380.01M | 340.42M | 301.09M | 233.83M | 243.03M | 223.11M | 194.13M |
| FCF per Share | 10.46 | 9.76 | 7.13 | 5.80 | 10.58 | 7.67 | 6.99 | 6.28 | 4.92 | 5.17 | 4.80 | 4.16 |
| Book Value | 3.16B | 3.46B | 3.60B | 2.98B | 2.53B | 2.11B | 1.63B | 1.32B | 1.05B | 836.77M | 733.07M | 672.20M |
| Cash & ST Investments | 213.77M | 194.61M | 276.77M | 233.91M | 246.30M | 229.45M | 238.96M | 195.44M | 163.79M | 117.63M | 117.95M | 160.02M |
| ROC Equity | -0.05 | 0.00 | 0.13 | 0.16 | 0.15 | 0.17 | 0.15 | 0.17 | 0.12 | 0.18 | 0.20 | 0.19 |